Individualized ovarian stimulation in IVF/ICSI treatment : it is time to stop using high FSH doses in predicted low responders by Leijdekkers, Jori A. et al.
© The Author 2019, Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email:
journals.permissions@oxfordjournals.org
This is an Open Access article distributed under the terms of the Creative Commons Non-Commercial Licence (CC BY NC) (https://creativecommons.org/licenses/by-nc/4.0/), which
permits the reuse, distribution and reproduction in any medium, except for commercial purpose, provided the original work is properly cited.
DEBATE
Individualized ovarian stimulation in
IVF/ICSI treatment: it is time to stop
using high FSH doses in predicted low
responders
Jori A. Leijdekkers1,*, Helen L. Torrance1, Nienke E. Schouten1,
Theodora C. van Tilborg1, Simone C. Oudshoorn1,
Ben Willem J. Mol2, Marinus J.C. Eijkemans3, and
Frank J.M. Broekmans1
1Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
2Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia 3Julius Centre for Health Sciences and Primary Care,
University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
*Correspondence address. Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Utrecht University,
Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: j.a.leijdekkers@umcutrecht.nl
Submitted on November 30, 2018; resubmitted on May 6, 2019; editorial decision on July 11, 2019
ABSTRACT: In IVF/ICSI treatment, the FSH starting dose is often increased in predicted low responders from the belief that it improves the
chance of having a baby by maximizing the number of retrieved oocytes. This intervention has been evaluated in several randomized controlled
trials, and despite a slight increase in the number of oocytes—on average one to two more oocytes in the high versus standard dose group—no
beneficial impact on the probability of a live birth has been demonstrated (risk difference, −0.02; 95% CI, −0.11 to 0.06). Still, many clinicians
and researchers maintain a highly ingrained belief in ‘the more oocytes, the better’. This is mainly based on cross-sectional studies, where the
positive correlation between the number of retrieved oocytes and the probability of a live birth is interpreted as a direct causal relation. If the
latter would be present, indeed, maximizing the oocyte number would benefit our patients. The current paper argues that the use of high FSH
doses may not actually improve the probability of a live birth for predicted low responders undergoing IVF/ICSI treatment and exemplifies the
flaws of directly using cross-sectional data to guide FSH dosing in clinical practice. Also, difficulties in the de-implementation of the increased
FSH dosing strategy are discussed, which include the prioritization of intermediate outcomes (such as cycle cancellations) and the potential
biases in the interpretation of study findings (such as confirmation or rescue bias).
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Introduction
As part of IVF/ICSI treatment, exogenous FSH is used for ovarian
stimulation in order to obtain oocytes and good-quality embryos
for transfer (Macklon et al., 2006). A large inter- and intra-individual
variation exists in the ovarian response to stimulation (Rustamov et al.,
2017), and a considerable proportion (6–35%) of the women produce
a low response (Oudendijk et al., 2012). This has been associated with
reduced live birth rates (LBRs) in single-cycle, retrospective studies
(Sunkara et al., 2011; Drakopoulos et al., 2016; Polyzos et al., 2018),
although studies that have analysed multiple cycles suggest that not
every low responder has reduced pregnancy prospects (Hendriks































Individualized FSH dosing strategies have been proposed to decrease
the variability in the ovarian response, with the objective to improve the
effectiveness of IVF/ICSI treatment (Popovic-Todorovic et al., 2003b;
Howles et al., 2006; La Marca et al., 2012; Yovich et al., 2012; Arce
et al., 2013; Lan et al., 2013; Magnusson et al., 2017). These strategies
rely on the putative dose–response relationship between the FSH
dose and the ovarian response (Arce et al., 2014) and use biomarkers
of the follicle cohort size to predict the response to stimulation
(Broer et al., 2013a,b). Guided by these predictions, the FSH starting
dose is often substantially increased in women with a predicted low
response.
Currently, consensus about the beneficial effects of such a dosing
strategy does not exist, due to differences in the interpretation of
the published scientific evidence. This paper addresses the main issues
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Figure 1 The effect of increased FSH doses (follitropin
delta) on the number of oocytes, number of embryos and
cumulative live birth rates in women with a predicted low
response (AMH levels of 0.7–2.1 ng/mL). Adapted with permis-
sion from Arce et al. (2014). AMH, anti-Müllerian hormone; rhFSH,
recombinant human FSH.
regarding the use of high FSH doses in predicted low responders and
challenges the clinical value of this strategy in IVF/ICSI treatment.
The origin of FSH dose
individualization in the
predicted low responder
The ovarian response to stimulation relies mostly on the number of
antral follicles present in the ovaries and potentially responsive to FSH
(Macklon et al., 2006). This number declines with advancing female age,
but a large variation exists between women of similar age (Broekmans
et al., 2007). Using the antral follicle count (AFC) and serum anti-
Müllerian hormone (AMH) levels, women with a reduced number of
antral follicles can be identified with reasonable accuracy (Broer et al.,
2013a). These so-called predicted low responders carry a substantial
risk of a low response to ovarian stimulation, defined as the retrieval of
less than four oocytes (Ferraretti and Gianaroli, 2014; Poseidon Group
et al., 2016).
In several large cross-sectional studies, women with a low number of
retrieved oocytes in response to a standard range of FSH dose were
observed to have a lower LBR than women with a higher number of
oocytes (Sunkara et al., 2011; Drakopoulos et al., 2016; Polyzos et al.,
2018). Based on this observed correlation, a common assumption has
gained ground that the probability of a live birth can be improved
for the individual low responder by increasing the ovarian response
to stimulation. Dose–response trials have indicated that the oocyte
yield may be increased by using higher FSH doses (Fig. 1) (Sterrenburg
et al., 2011; Arce et al., 2014), so that, in daily practice, predicted low
responders are treated with doses far above the standard FSH dose of






























































































































Still, the previously mentioned cross-sectional studies provide no
information on whether such high FSH doses actually improve the
chance of a live birth for the individual low responder. The observations
only correlate the number of oocytes to the chance of a live birth but
fail to inform on the effectiveness of interventions that alter the ovarian
response. The fact that women with a higher number of oocytes
have better pregnancy prospects does not automatically imply that the
ovarian response is a ‘key modifiable determinant’ for the chance of a
live birth in IVF/ICSI treatment. Factors related to both the ovarian
response and the chance of a live birth, such as female age, may
have a much more prominent role and are unaffected by FSH dosing.
Therefore, even though a high FSH dose may effectively increase the
oocyte yield, this may not translate into a similar positive effect on the
LBR.
To answer the question of whether increasing the oocyte yield
by using high FSH doses will actually lead to improved pregnancy
chances, an interventional study design is required in which predicted
low responders are randomly allocated to a high versus a standard FSH
dose.
Comparative studies of FSH
dosing in predicted low
responders
Several randomized controlled trials (RCTs) have been performed on
the effectiveness of FSH dose individualization. These RCTs can be
categorized into two types: (i) trials that compare different FSH doses
in a defined patient category (direct dose comparison studies) and (ii)
trials that compare the use of an individualized FSH dosing algorithm to
a standard dosing strategy (dosing algorithm studies). Both study types
were recently summarized in an extensive systematic review (Lensen
et al., 2018).
Direct dose comparison studies
In predicted low responders, eight RCTs directly compared a higher
versus a lower FSH dose (see Table I) (Harrison et al., 2001; Klinkert
et al., 2005; Berkkanoglu and Ozgur, 2010; Arce et al., 2014; Lefebvre
et al., 2015; Bastu et al., 2016; Youssef et al., 2016; van Tilborg
et al., 2017b). Only one of these trials was primarily powered to
detect differences in cumulative LBR, including the results of both
fresh and frozen embryo transfers (FET), for women with a predicted
low (AFC 0–7) and suboptimal (AFC 8–10) response (van Tilborg
et al., 2017b). This trial revealed no significant differences in cumulative
LBR between the higher FSH dose (225 or 450 IU/day for predicted
suboptimal and low responders, respectively) versus the standard
FSH dose (150 IU/day) over 18 months of IVF/ICSI treatment (risk
difference (RD), −0.02; 95% CI, −0.11 to 0.06). Moreover, the cost-
effectiveness analysis revealed that the higher FSH dose increases the
costs of treatment with a mean difference of e1099 per woman (95%
CI, e562–e1591).
In this particular trial, small dose increments between cycles (max-
imum, 50 IU/day) were permitted if a woman had a poor response
in the standard dose arm (van Tilborg et al., 2012). This occurred in
64% of the women between the first and second cycle, with a median
increment of 50 IU/day (interquartile range, 50–50). Therefore, the
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Table I Dose comparison studies in predicted low responders in IVF/ICSI treatment.






225 or 450 IU 150 IU
van Tilborg et al., 2017b AFC ≤ 10 CLBR over 18 months (fresh + FET) 106/250 (42.4) 117/261 (44.8) 0.95 (0.78–1.15)
First-cycle LBR (fresh + FET) 44/250 (17.6) 52/261 (19.9) 0.88 (0.62–1.27)
First cycle LBR (fresh) 37/250 (14.8) 41/261 (15.7) 0.94 (0.63–1.42)
300 IU 150 IU
Klinkert et al., 2005 AFC ≤ 4 First cycle OPR (fresh) 1/26 (3.8) 2/26 (7.7) 0.50 (0.05–5.18)
450 IU 150 IU
Youssef et al., 2018∗ Female age ≥ 35, or
bFSH > 10 IU/L, or
AFC ≤ 4, or
Previous poor responsea
First cycle OPR (fresh) 27/199 (13.6) 25/195 (12.5) 1.06 (0.64–1.76)
400 IU 300 IU
Harrison et al., 2001 bFSH > 8.5 IU/L First-cycle CPR (fresh) 2/24 (8.3) 2/24 (8.3) 1.00 (0.15–6.53)
450 IU 300 IU
Bastu et al., 2016 ESHRE Bologna criteria
(Ferraretti et al., 2011)
First cycle OPR (fresh) 4/31 (12.9) 5/31 (16.1) 0.80 (0.24–2.70)
450 IU 300 IU
Berkkanoglu and
Ozgur, 2010∗∗
AFC ≤ 11 First cycle LBR (fresh) 3/39 (7.7)
600 IU
4/38 (10.5) 0.73(0.18–3.05)
4/42 (9.5) 0.90 (0.24–3.36)
600 IU 450 IU
Lefebvre et al.,2015 bFSH > 10 IU/L, or
AMH < 1.0 ng/mL, or
AFC ≤ 8, or
Previous poor responseb
First cycle LBR (fresh) 25/180 (13.8) 19/176 (10.8) 1.29 (0.74–2.25)
6.9ug 5.2 ug
Arce et al., 2014∗∗∗ 0.7–2.1 ng/mL First cycle LBR (fresh + FET)






















RR, relative risk; AFC, antral follicle count; CLBR, cumulative live birth rate; LBR, live birth rate; FET, frozen embryo transfer; OPR, ongoing pregnancy rate; bFSH, basal FSH; CPR,
clinical pregnancy rate; AMH, anti-Müllerian hormone.
∗This study compared 450-IU HMG in a GnRH agonist protocol to 150-IU FSH in a GnRH antagonist protocol.
∗∗This study quasi-randomized patients according to the last number of their patient number.
∗∗∗This five-arm study reported dosages of a new recombinant human FSH (follitropin delta, FE 999049) in micrograms, which cannot be directly translated into IU.
aDefined as ≤5 retrieved oocytes.
bDefined as <5 oocytes, <8 follicles or cycle cancellation on an FSH dose of ≥300 IU/day.
first complete cycle results may reflect the difference between the stan-
dard dose and the increased FSH dose the most clearly. This first cycle
analysis, including the results of both fresh and FET cycles, revealed
no significant difference in LBR (RD, −0.02; 95% CI, −0.08 to 0.05).
Additionally, analysis of only the predicted low responders (AFC 0–7)
revealed no significant differences in cumulative LBR over 18 months
(RD, −0.06; 95% CI, −0.18 to 0.06). The first complete cycle analysis
in this particular group, including the results of fresh and FET cycles,




















None of the seven other direct dose comparison RCTs revealed
a significant difference in pregnancy rates when using high FSH
doses (Table I). Nonetheless, due to the small study samples, point
estimates were imprecise and differences in either direction could
not be ruled out based on these data. Unfortunately, all studies
differed markedly with regard to their study population and FSH
dose comparison, which hindered pooling of the results to increase
precision. Still, although acknowledging the limitations of the studies,
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of them support the use of high FSH doses in predicted low
responders.
Dosing algorithm studies
In addition to the seven dose comparison RCTs, five dosing algorithm
studies compared an individualized dosing strategy to a standard dose
(Popovic-Todorovic et al., 2003a; Olivennes et al., 2015; Allegra et al.,
2017; Nyboe Andersen et al., 2017; van Tilborg et al., 2017a). Only
one small trial, which included mostly women with a good prognosis,
revealed an increase in the ongoing pregnancy rate (relative risk, 1.50;
95% CI, 1.03–2.18) (Popovic-Todorovic et al., 2003a). Taken together
in a meta-analysis, the trials demonstrated a pooled odds ratio of 1.04
(95% CI, 0.88–1.23) for a fresh cycle live birth (Lensen et al., 2018).
However, in contrast to the dose comparison studies, dosing algorithm
studies do not focus on the predicted low responders in particular
but merely on the IVF/ICSI population as a whole. Therefore, as both
higher and lower FSH doses are used in these trials, depending on the
specific algorithm that is used, conclusions regarding the effectiveness
of high FSH doses for predicted low responders cannot be drawn.
Statistical power of comparative studies
As none of the RCTs have shown an improvement in LBR after an
increased FSH dose (Table I), the question arises as to whether we can
now conclude that high FSH doses actually have no beneficial impact
for predicted low responders. To answer this question, the issue of
statistical significance needs to be addressed first. Commonly, P values
are used as an arbitrary threshold of significance, and scientific conclu-
sions are often based on whether effects are found to be statistically
significant or not (Amrhein et al., 2019). However, the lack of statistical
significance, as usually indicated by a P value > 0.05 or a CI that includes
zero, does not necessarily mean that an effect is absent (Wasserstein
et al., 2019). Therefore, instead of looking at statistical significance as a
dichotomizing measure, the uncertainty and variation in study findings
need to be better highlighted by a more detailed description of the
point estimates and CIs (Amrhein et al., 2019).
When considering the data of the previously mentioned trial (van
Tilborg et al., 2017b), the point estimate suggests a decrease in cumula-
tive LBR of 2 percentage points with the high FSH dose (cumulative LBR
of 44.8% vs 42.4%). Nonetheless, the 95% CI indicates that the high
FSH dose may also result in a decrease in LBR of 11 percentage points
or an increase of 6 percentage points. Therefore, in order to claim that
the results show no important differences between the higher dose
and the standard dose, all values inside this particular interval must be
deemed as practically unimportant. Since such a claim is highly prone to
contradicting clinical opinions, no uniform conclusions can be expected
and an even larger trial may be needed to increase the precision of the
point estimate.
Yet, at this moment, there is no proper evidence to justify the use of
high FSH doses in predicted low responders. The findings of the largest
dose comparison RCT even suggest a potential decrease in LBR when
using a higher FSH dose (Table I). Moreover, it increases the costs of
treatment (van Tilborg et al., 2017b). Therefore, as the use of high FSH
doses could potentially harm women undergoing IVF/ICSI treatment,
the standard FSH dose of 150 IU/day should be considered as the





























































































































The more oocytes, the better?
In predicted low responders, a high FSH dosage may increase the
number of retrieved oocytes by, on average, one to two more oocytes
and substantially reduces the rate of cycle cancellations for insufficient
follicular growth (Youssef et al., 2016; van Tilborg et al., 2017b). Yet,
as summarized in the previous paragraph, the randomized comparisons
between a higher FSH dose and a standard FSH dose suggest that the
increase in oocyte number and reduction in cycle cancellation rate
do not actually improve the (cumulative) probability of a live birth.
These findings may urge clinicians to refrain from cycle cancellations
as a repeat cycle with a higher dosage will probably not improve the
chance of a live birth. The common belief in ‘the more oocytes, the
better’, that was derived from large cross-sectional studies (Sunkara
et al., 2011; Drakopoulos et al., 2016; Polyzos et al., 2018), may thus
require serious reconsideration.
Why an increased FSH dose does not
improve LBR
More likely, the number of retrieved oocytes only partially mirrors
the prognostic profile of an individual woman (Fig. 2). This prognostic
profile is predominantly determined by a combination of well-known
factors, such as the woman’s age and the genetic quality of the oocytes
(Munné et al., 1993; Hassold and Hunt, 2001; Broekmans et al.,
2007), but also by unknown factors at, for instance, the sperm or
endometrium level (Simon et al., 2014; Gallos et al., 2018; Liu et al.,
2018). Women with a poor prognostic profile (e.g. advanced female
age, reduced oocyte quality) often also have a reduced quantitative
ovarian reserve and a lower number of retrieved oocytes. Using a
higher FSH dose in order to increase the number of oocytes is unlikely
to improve the probability of a live birth, as the main prognostic
characteristics of the individual woman remain unaltered. Moreover,
since predicted low responders by definition have a reduced number
of antral follicles that are responsive to FSH, a higher FSH dose may
not actually increase the oocyte yield for every woman.
Increased FSH doses and oocyte/embryo
quality
The relationship between the number of oocytes and their quality
may be expressed by the ploidy status of the embryo, as can be
assessed through PGS (Twisk et al., 2006). Recent studies suggest that
the chromosomal status of embryos mainly determines the success of
implantation (Capalbo et al., 2014), although many more factors may
be involved in the reproductive potential of embryos. In retrospective
data, the embryo aneuploidy rate has appeared to be unrelated to the
number of retrieved oocytes or embryos, within female age classes
(Ata et al., 2012; Venetis et al., 2019). Women with a higher number
of oocytes or embryos were thus observed to have a higher absolute
number of euploid embryos (La Marca et al., 2017). Nonetheless, these
were all observational studies that provide no valid information on
whether an intervention that manipulates the ovarian response, such
as increased FSH dosing, will actually improve this absolute number of
good-quality/euploid embryos for an individual woman.
Several studies have aimed to investigate whether the FSH dose
affects the embryo aneuploidy rate (Barash et al., 2017; Sekhon et al.,
2017; Wu et al., 2018). These studies have revealed no significant
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Figure 2 Relationship between the prognostic profile of an individual woman, the number of oocytes and the probability of a live
birth in IVF/ICSI treatment.
Figure 3 Relationship between the number of oocytes,
embryos and chromosomally normal embryos on the basis
of fluorescent in situ hybridization (FISH) results, following
a conventional (225 IU/day) and mild (150 IU/day) ovar-











































































association but were prone to confounding and selection bias due to
their retrospective design. Prospective randomized studies that com-
pared different FSH doses revealed that a higher FSH dose, although
increasing the number of oocytes, reduced the proportion of high-
quality/euploid blastocysts (see Figs. 1 and 3) (Baart et al., 2007; Arce
et al., 2014). The higher FSH dose thereby resulted in similar abso-
lute numbers of good-quality/euploid embryos and had no beneficial
impact on LBR. These findings suggest that the surplus of oocytes,
obtained by using an increased FSH dose, is of lower quality with a
high proportion of nuclear immaturity and a compromised fertilization,
development and implantation potential. This supports the notion that
a certain hierarchy exists among antral follicles in their capability to
respond to exogenous FSH, in which the most sensitive follicles at that
time will develop with standard FSH exposure and provide the best
quality oocytes (Kovalevsky and Patrizio, 2005; Patrizio et al., 2007;
Patrizio and Sakkas, 2009; Martin et al., 2010; Doherty et al., 2014).
Recruiting the few oocytes that have the potential to fertilize and
develop into a competent embryo with a high implantation capacity
therefore seems to be more important than striving for a maximal
response with additional oocytes that do not fertilize or develop into
good-quality embryos.
Why do we continue the high
dosing strategy?
The prioritization of intermediate outcomes
Many clinicians seem reluctant to use a standard FSH dose of 150 IU/-
day in predicted low responders. This is partly explained by the
prioritization of intermediate outcomes, including the risk of a cycle
cancellation or the occurrence of a low response. Some even suggest
that a higher FSH dose is more beneficial than a standard dose, based
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Figure 4 Factors influencing the use of increased FSH starting doses in women with a predicted low response. LBR, live birth
rate.
the same level of cumulative LBR in predicted low responders (Nyboe
Andersen et al., 2017; La Marca et al., 2018). From a certain per-
spective, improving intermediate outcomes is satisfactory for both the
patient and the doctor. In women with a predicted suboptimal response
(AFC 8–10), for example, the retrieval of four oocytes instead of
eight could be perceived as a clinical failure, even when this has no
negative impact on the chance of a live birth (Baart et al., 2007; Arce
et al., 2014). By postponing any negative annotations until after the
transfer of an embryo, the failure of treatment becomes distanced
from directly modifiable treatment variables. This might beneficially
impact the patient–doctor relationship and reduce the psychological
stress during treatment, e.g. by lowering the risk of a cycle cancellation
(Troude et al., 2014). Ultimately, this could even improve the continu-
ation of treatment (Olivius et al., 2004; Rajkhowa et al., 2006; Brandes
et al., 2009). However, from the dose comparison trial evaluating
cumulative LBR (including the results of both fresh and FET cycles)
across 18 months of treatment, which thereby also includes the impact
of treatment discontinuation, no improvements of the cumulative LBR
with high FSH doses were noted despite the improved intermediate
outcomes (van Tilborg et al., 2017b). Therefore, targeting expecta-














































cycles, may be a more appropriate method to help couples cope with
failures after repeated attempts and alleviate the psychological stress
during treatment (Dancet et al., 2011; Holter et al., 2014; McLernon
et al., 2016; Leijdekkers et al., 2018).
The bias in the interpretation of research
Without prior demonstration of a benefit, the use of FSH doses >
150 IU/day has been readily integrated into IVF/ICSI treatment. De-
implementation of this routine strategy now requires compelling stud-
ies demonstrating ineffectiveness (Scott and Elshaug, 2013). However,
the threshold of research to be compelling is high and may be prone
to several biases (see Fig. 4) (Kaptchuk, 2003). First, study results
that contradict prior expectations are often less readily accepted than
those confirming them (confirmation bias). Such contradicting results
are prone to higher standards and selective finding of faults in the
study design or execution (rescue bias). Additionally, an over-reliance
on pathophysiological reasoning may cause a less skeptical attitude
towards results that are supported by a bio-plausible mechanism and
lead to the use of intermediate outcomes that do not necessarily trans-
late into patient-important benefits (mechanism bias). Finally, clinicians
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generally tend to choose action over inaction, even if the benefits of
the action are small or even absent (pro-intervention bias) (Kaptchuk,
2003; Doust and Del Mar, 2004; Scott and Elshaug, 2013).
The appraisal of the results of the dose comparison RCTs on
increased FSH dosing in predicted low responders is prone to these
biases, mainly due to the strong belief in ‘the more oocytes, the
better’ (Sunkara et al., 2011; Drakopoulos et al., 2016; Polyzos et al.,
2018). Opponents of the standard dosing strategy often use the lack
of compelling evidence as an argument to give the use of higher FSH
doses ‘the benefit of the doubt’ (La Marca et al., 2018). This seems
to indicate that a higher level of certainty is required to claim the
lack of benefit, than that is needed to justify the continued use of
the now routine and potentially harmful practice at the discretion of
the clinician. The skepticism towards previous studies on FSH dosing
raises the question of how much research is needed to stop the use
of an unproven and costly treatment strategy (Haahr et al., 2018;
La Marca et al., 2018; Mendoza-Tesarik and Tesarik, 2018; Nelson
and Anderson, 2018; Sunkara and Polyzos, 2018; van Tilborg et al.,
2018).
How to proceed?
FSH starting doses > 150 IU/day should not be used as a standard
dosing strategy in women with a predicted low response undergoing
IVF/ICSI treatment, as they have no proven beneficial impact on
the chance of a live birth and they increase the costs of treatment
(van Tilborg et al., 2017b). Clinicians and researchers who are not
convinced by the evidence to date are challenged to limit the use
of higher FSH doses to research settings, thereby generating the
data that actually support the belief in ‘the more oocytes, the
better’.
Conclusion
In conclusion, using high FSH doses in predicted low responders
undergoing IVF/ICSI treatment is based on feeble assumptions from
retrospective cross-sectional studies about the importance of the
number of oocytes in relation to the probability of a live birth. The
highly ingrained belief in ‘the more oocytes, the better’ has induced
the routine use of high FSH doses in predicted low responders, but is
now contradicted by several comparative trials that have failed to show
that a higher number of oocytes actually improve the probability of a
live birth for an individual woman. Therefore, it is time to reconsider
this belief and stop the use of high FSH starting doses in clinical
practice.
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